Asset Details
Do you wish to reserve the book?
Bifidobacterium animalis Subsp. Lactis BB-12 administration in early childhood: A randomized clinical trial of effects on oral colonization by mutans streptococci and the probiotic
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Bifidobacterium animalis Subsp. Lactis BB-12 administration in early childhood: A randomized clinical trial of effects on oral colonization by mutans streptococci and the probiotic
Do you wish to request the book?
Bifidobacterium animalis Subsp. Lactis BB-12 administration in early childhood: A randomized clinical trial of effects on oral colonization by mutans streptococci and the probiotic
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Bifidobacterium animalis Subsp. Lactis BB-12 administration in early childhood: A randomized clinical trial of effects on oral colonization by mutans streptococci and the probiotic
2012
Overview
A randomized clinical trial studied the effects of early ad-ministration of Bifidobacterium animalis subsp. lactis BB-12 (BB-12) on oral colonization of (1) mutans streptococci (MS), and (2) BB-12. In this double-blind, placebo-controlled study, infants (n = 106) received probiotic bacteria (BB-12 group), xylitol (X group), or sorbitol (S group). Test tablets were administered twice a day (from the age of 1-2 months) with a novel slow-release pacifier or a spoon (daily dose of BB-12 1010 CFU, polyol 200-600 mg). Samples were collected from mucosa/teeth at the age of 8 months and 2 years for BB- 12 determination (qPCR) and plate culturing of MS (MSB, TYCSB), lactobacilli (Rogosa) and yeasts (Sabouraud). The MS levels of the mothers were determined (Dentocult SM Strip Mutans). The baseline characteristics of the three groups were similar. Mean duration of tablet delivery was 14.9 ± 6.7 months. In all groups, >90% of the mothers showed high MS counts (log CFU ≧5). MS colonization percentages of the children at the age of 2 years were rather low (BB-12 group: 6%; X group: 31%; S group: 10%; p < 0.05). The levels of lactobacilli and yeasts did not differ between the groups. BB-12 cell counts barely exceeding the detection limit were found in three of the oral samples of the 8-month-old children; however, the 2-year samples did not contain BB-12. The early administration of BB-12 did not result in permanent oral colonization of this probiotic or significantly affect MS colonization in the children.
Subject
/ Bifidobacterium - isolation & purification
/ Bifidobacterium - physiology
/ Candida albicans - isolation & purification
/ Candida albicans - physiology
/ Dental Plaque - microbiology
/ Female
/ Humans
/ Infant
/ Lactobacillus - isolation & purification
/ Male
/ Placebos
/ Probiotics - administration & dosage
/ Probiotics - therapeutic use
/ Sorbitol - administration & dosage
/ Streptococcus mutans - physiology
/ Streptococcus sobrinus - isolation & purification
/ Streptococcus sobrinus - physiology
/ Tablets
